These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 14713926)

  • 61. Does nephrotoxicity develop less frequently when vancomycin is combined with imipenem-cilastatin than with meropenem? A comparative study.
    Hakeam HA; AlAnazi L; Mansour R; AlFudail S; AlMarzouq F
    Infect Dis (Lond); 2019 Aug; 51(8):578-584. PubMed ID: 31122098
    [No Abstract]   [Full Text] [Related]  

  • 62. Neurotoxicity of carbapenem antibacterials.
    Norrby SR
    Drug Saf; 1996 Aug; 15(2):87-90. PubMed ID: 8884160
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
    J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of imipenem/cilastatin for treatment of infection in an elderly population.
    Smith MD; Bielawska C; Kelsey MC; Rai G; Deaney NB
    J Antimicrob Chemother; 1988 Apr; 21(4):481-7. PubMed ID: 3378960
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins.
    Romano A; Gaeta F; Valluzzi RL; Alonzi C; Maggioletti M; Zaffiro A; Caruso C; Quaratino D
    Allergy; 2013 Dec; 68(12):1618-21. PubMed ID: 24180646
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
    Eklund AE; Nord CE
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
    Norrby SR; Finch RG; Glauser M
    J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections.
    Attanasio E; Russo P; Carunchio G; Basoli A; Caprino L
    Dig Surg; 2000; 17(2):164-72. PubMed ID: 10781982
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Drug utilization evaluation of imipenem/cilastatin in patients with renal dysfunction.
    Sheakely ML; Nicolau DP; Agner SI
    Ann Pharmacother; 1993; 27(7-8):981-2. PubMed ID: 8364293
    [No Abstract]   [Full Text] [Related]  

  • 70. Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis.
    Strandvik B; Malmborg AS; Bergan T; Michalsen H; Storrøsten OT; Wretlind B
    J Antimicrob Chemother; 1988 Apr; 21(4):471-80. PubMed ID: 3132441
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Successful meropenem desensitization in a patient with cystic fibrosis.
    Wilson DL; Owens RC; Zuckerman JB
    Ann Pharmacother; 2003 Oct; 37(10):1424-8. PubMed ID: 14519038
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin.
    Quattropani C; Schneider M; Helbling A; Zimmermann A; Krähenbühl S
    Liver; 2001 Jun; 21(3):213-6. PubMed ID: 11422785
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The risk of seizures among the carbapenems: a meta-analysis.
    Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA
    J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rapid imipenem/cilastatin desensitization for multidrug-resistant Acinetobacter pneumonia.
    Gorman SK; Zed PJ; Dhingra VK; Ronco JJ
    Ann Pharmacother; 2003 Apr; 37(4):513-6. PubMed ID: 12659606
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
    Geddes A; Thaler M; Schonwald S; Härkönen M; Jacobs F; Nowotny I
    J Antimicrob Chemother; 1999 Dec; 44(6):799-810. PubMed ID: 10590282
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
    Youssif E; Aseeri M; Khoshhal S
    J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neurological complication during imipenem/cilastatin therapy in uraemic patients.
    Campise M
    Nephrol Dial Transplant; 1998 Jul; 13(7):1895-6. PubMed ID: 9681765
    [No Abstract]   [Full Text] [Related]  

  • 78. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
    Romanelli G; Cravarezza P; Pozzi A; Franchino L; Ravizzola G; Zulli R; Donati P; Prometti P; Grassi V
    J Chemother; 2002 Dec; 14(6):609-17. PubMed ID: 12583553
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Pharmacoeconomics of meropenem versus imipenem/cilastatin].
    Marquina MC; Giráldez J; Idoate A
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():45-50. PubMed ID: 9410069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.